Crinetics Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Crinetics Pharmaceuticals

04/08/2026 22:01

Crinetics Pharmaceuticals Inc CRNX.OQ reported a quarterly adjusted loss of $1.14​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.23.  The mean expectation of fourteen analysts for the quarter was for a loss of $1.21 per share. Wall Street expected results to range from $-1.35 to -87 cents per share.
Revenue rose 2,336.3% to $25.12 million from a year ago; analysts expected $14.84 million. 
Crinetics Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.14​.
The company reported a quarterly loss of $120.86 million.
Crinetics Pharmaceuticals Inc shares had risen by 123.8% this quarter and gained 79.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.3% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 13 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $85.00, about 1.5% above its last closing price of $83.76
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.21
-1.14
Beat
Mar. 31 2026 
-1.24
-1.23
Beat
Dec. 31 2025 
-1.37
-1.29
Beat
Sep. 30 2025 
-1.26
-1.38
Missed